Poulton Jeffrey V. 4

Accession 0001735276-26-000013

CIK 0001178670other

View on SEC.gov Company Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 4:22 PM ET

Size

43.9 KB

Accession

0001735276-26-000013

Insider Transaction Report

Form 4

Period: 2026-01-11

ALNYLAM PHARMACEUTICALS, INC.ALNY

Poulton Jeffrey V.

EVP, Chief Financial Officer

Transactions

Award
Common Stock
[F1]
2026-01-11+6,193→ 60,245 total
Sale
Common Stock
[F2][F3]
2026-01-12$353.95/sh−72$25,484→ 60,173 total
Sale
Common Stock
[F2][F4]
2026-01-12$355.16/sh−78$27,702→ 60,095 total
Sale
Common Stock
[F2][F5]
2026-01-12$356.09/sh−76$27,063→ 60,019 total
Sale
Common Stock
[F2][F6]
2026-01-12$357.17/sh−176$62,862→ 59,843 total
Sale
Common Stock
[F2][F7]
2026-01-12$358.18/sh−226$80,949→ 59,617 total
Sale
Common Stock
[F2][F8]
2026-01-12$359.14/sh−156$56,026→ 59,461 total
Sale
Common Stock
[F2][F9]
2026-01-12$360.22/sh−284$102,302→ 59,177 total
Sale
Common Stock
[F2][F10]
2026-01-12$361.45/sh−181$65,422→ 58,996 total
Sale
Common Stock
[F2][F11]
2026-01-12$362.38/sh−135$48,921→ 58,861 total
Sale
Common Stock
[F2][F12]
2026-01-12$363.55/sh−87$31,629→ 58,774 total
Sale
Common Stock
[F2][F13]
2026-01-12$364.83/sh−365$133,163→ 58,409 total
Sale
Common Stock
[F2][F14]
2026-01-12$365.56/sh−405$148,052→ 58,004 total
Sale
Common Stock
[F2][F15]
2026-01-12$366.41/sh−92$33,710→ 57,912 total
Sale
Common Stock
[F2][F16]
2026-01-12$367.40/sh−76$27,922→ 57,836 total
Sale
Common Stock
[F2][F17]
2026-01-12$368.62/sh−170$62,665→ 57,666 total
Sale
Common Stock
[F2][F18]
2026-01-12$369.48/sh−73$26,972→ 57,593 total
Sale
Common Stock
[F2][F19]
2026-01-12$370.87/sh−36$13,351→ 57,557 total
Sale
Common Stock
[F2][F20]
2026-01-12$372.46/sh−6$2,235→ 57,551 total
Sale
Common Stock
[F2][F21]
2026-01-12$374.44/sh−25$9,361→ 57,526 total
Sale
Common Stock
[F2]
2026-01-12$375.65/sh−34$12,772→ 57,492 total
Sale
Common Stock
[F2]
2026-01-12$377.82/sh−27$10,201→ 57,465 total

Holdings

Common Stock
[F22]
(indirect: by Managed Account)
57

Footnotes (22)

[F1]On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026.
[F10]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F11]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F12]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F13]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F14]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F15]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F16]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F17]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F18]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F19]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations.
[F20]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F21]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F22]Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
[F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F8]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F9]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Signature

By: Brett Budzinski, Attorney-in-Fact For: Jeffrey V. Poulton|2026-01-14

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

ALNYLAM PHARMACEUTICALS, INC.

CIK 0001178670

→

Entity typeother

Related Parties

filerCIK 0001782962

Filing Metadata

Form type: 4
Filed: Jan 13, 7:00 PM ET
Accepted: Jan 14, 4:22 PM ET
Size: 43.9 KB

View on SEC.gov